ClinicalTrials.Veeva

Menu
I

ICH Study Center GmbH & Co. KG | Hamburg, Germany

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenacapavir
Bictegravir
JNJ-56136379
JNJ-73763989
TAF
GS-3242
Tenofovir disoproxil fumarate
Entecavir
Tenofovir alafenamide
Tenofovir Alafenamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B.The goal of Phase 2, Part A is to assess...

Enrolling
HIV-1-infection
Drug: GS-3242 Injection
Drug: Lenacapavir Tablet

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting
HIV-1-infection
Drug: BIC/LEN FDC
Drug: Bictegravir

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Oral Lenacapavir Placebo

Trial sponsors

Gilead Sciences logo
Janssen (J&J Innovative Medicine) logo
H
Merck Sharp & Dohme (MSD) logo
N
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems